Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 24, 2021	Jun. 16, 2022	Sep. 24, 2021
Net sales	$ 465.4	$ 550.4	$ 507.2	$ 874.6	$ 1,611.6
Cost of sales	449.9	552.1	319.2	582.0	958.4
Gross profit	15.5	(1.7)	188.0	292.6	653.2
Selling, general and administrative expenses	129.2	159.5	127.3	275.3	408.3
Research and development expenses	28.3	34.5	47.3	65.5	166.3
Restructuring charges, net	2.2	3.3	11.0	9.6	17.5
Non-restructuring impairment charges	0.0	0.0	0.0	0.0	64.5
Losses on divestiture		0.0		0.0	0.8
Opioid-related litigation settlement loss	0.0	0.0	125.0	0.0	125.0
Operating loss	(144.2)	(199.0)	(122.6)	(57.8)	(129.2)
Interest expense	148.0	169.1	48.7	108.6	160.7
Interest income	(1.3)	(1.4)	0.0	(0.6)	(1.9)
Other expense, net	(5.1)	0.8	(3.5)	(14.6)	15.9
Reorganization items, net	(14.2)	(17.7)	(126.2)	(630.9)	(329.2)
Loss from continuing operations before income taxes	(310.2)	(383.6)	(301.0)	(811.3)	(601.3)
Income tax benefit	(24.9)	(34.6)	(32.0)	(497.3)	(81.9)
Loss from continuing operations	(285.3)	(349.0)	(269.0)	(314.0)	(519.4)
Income from discontinued operations, net of income taxes	0.4	$ 0.4	5.3	$ 0.9	$ 6.0
Net loss	$ (284.9)		$ (263.7)
Basic (loss) income per share (Note 7):
Loss from continuing operations	$ (21.61)	$ (26.44)	$ (3.18)	$ (3.70)	$ (6.13)
Income from discontinued operations	0.03	0.03	0.06	0.01	0.07
Net loss	$ (21.58)	$ (26.41)	$ (3.11)	$ (3.69)	$ (6.06)
Basic weighted-averaged shares outstanding (in shares)	13.2	13.2	84.7	84.8	84.7
Diluted (loss) income per share (Note 7):
Loss from continuing operations	$ (21.61)	$ (26.44)	$ (3.18)	$ (3.70)	$ (6.13)
Income from discontinued operations	0.03	0.03	0.06	0.01	0.07
Net loss	$ (21.58)	$ (26.41)	$ (3.11)	$ (3.69)	$ (6.06)
Diluted weighted-average shares outstanding (in shares)	13.2	13.2	84.7	84.8	84.7
Retained Earnings (Deficit)
Net loss	$ (284.9)	$ (348.6)	$ (263.7)	$ (313.1)	$ (513.4)